The current study, hence, adds details to this established understanding, suggesting that immunomodulation via IL-6 and IDO1 of the tumor microenvironment by MSCs during cisplatin treatment, even at subtoxic doses, is a relevant mechanism to consider. Here, IDO1 is linked to neoplasm.